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BACKGROUND: Clinical guidelines recommend depres-
sion screening in patients with coronary artery disease
(CAD), but how to accomplish this is unclear.
OBJECTIVE: We evaluated the test characteristics of
the two-item Patient Health Questionnaire (PHQ-2), the
nine-item Patient Health Questionnaire (PHQ-9), and a
two-step screening approach (PHQ-2 then PHQ-9 if
positive on PHQ-2), compared with the Computerized
Diagnostic Interview Schedule (C-DIS) for major depres-
sion. We also evaluated a “PHQ diagnosis” of depres-
sion, requiring five of nine symptoms “more than half
the days,” compared with the C-DIS.
DESIGN: Cross-sectional study of 1,024 outpatients
with CAD.
MAIN RESULTS: Two hundred twenty-four patients
(22%) had current major depression. Optimal cutpoints
were ≥2 for the PHQ-2 (82% sensitive, 79% specific) and
≥6 for the PHQ-9 (83% sensitive, 76% specific). The
two-step screening approach was less sensitive (75%),
but more specific (84%), than the PHQ-2 or PHQ-9
alone. The “PHQ diagnosis” had low sensitivity (28%),
but high specificity (96%).
CONCLUSIONS: Cutpoints of ≥2 on the PHQ-2 and ≥6
on the PHQ-9 had similar test characteristics. A two-
step approach using the PHQ-2 followed by the PHQ-9
was no better than either instrument alone. A “PHQ
diagnosis” of depression had high specificity, but poor
sensitivity.
KEY WORDS: diagnostic accuracy; sensitivity; specificity; cardiovascular
disease; depression; screening.
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INTRODUCTION
Major depressive disorder (MDD) is present in approximately
20% of patients with cardiovascular disease (CVD).
1,2 Several
clinical guidelines
3,4,5 recommend depression screening in
patients with CVD, although none specifies what procedures
or instruments should be used.
A recent National Heart, Lung, and Blood Institute (NHLBI)
Working Group
6 recommended a two-step approach to screen-
ing in research studies in which the two-item version of the
Patient Health Questionnaire (PHQ-2)
7 is used as an initial
screen, and the nine-item version (PHQ-9)
8 is administered to
patients positive on the PHQ-2 to identify patients likely to
have MDD based on a structured clinical interview. The PHQ-9
is self-administered and easily scored, maps onto the nine
symptoms from the DSM-IV classification for MDD, and can be
used to track symptoms.
8,9 Recommended cutoff scores to
identify patients in primary care who would likely be positive
for MDD based on a clinical interview are ≥10 for the PHQ-9
and ≥3 for the PHQ-2.
7
It has also been suggested that that a “PHQ diagnosis” of
MDD can be obtained from the PHQ-9 based on five of nine
depressive symptoms present at least half of the days in the
past 2 weeks, including depressed mood or anhedonia.
8
However, two systematic reviews
9,10 reported that this method
had similar accuracy to the cutoff score method for identifying
patients who met MDD criteria based on a structured clinical
interview. These reviews found that the PHQ-9 had good
sensitivity (77% and 80%) and specificity (94% and 92%) in
primary care settings,
9,10 but one review showed that recom-
mended cutoff scores for the PHQ-9 had poor sensitivity in
three of six specialty medicine samples (50% to 69%).
10
McManus et al.
11 found that cutoff points recommended for
primary care patients resulted in poor sensitivity for the PHQ-2
(39%) and PHQ-9 (54%), compared to a diagnosis of MDD
based on the Computerized Diagnostic Interview Schedule (C-
DIS),
12 among 1,024 outpatients with stable coronary artery
disease (CAD) from the Heart and Soul Study, but did not
identify an optimal screening cutoff. Stafford et al.
13 reported
that a cutoff score of ≥6 optimized sensitivity (83%) and
specificity (79%) among CAD outpatients, but this was based
on a relatively small sample (N=193, MDD=35).
The objective of this study was to assess the test character-
istics of the PHQ-2 and PHQ-9 compared to an MDD diagnosis
using the C-DIS in CAD patients from the Heart and Soul
Study using recommended primary care cutoffs, alternative
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2014cutoffs, the two-step approach recommended by the NHLBI
Working Group, and a “PHQ diagnosis.”
METHODS
Patients and Procedures
Methods of the Heart and Soul Study have been described
previously.
11 Eligible patients were identified through adminis-
trative databases as having CAD, defined as history of MI,
angiographic evidence of ≥50% stenosis in ≥1c o r o n a r yv e s s e l ,
previous evidence of exercise-induced ischemia by cardiac stress
testing, history of coronary revascularization, and/or diagnosis
ofCADbyan internistorcardiologist.Invitations toparticipatein
the study were mailed to 15,438 eligible patients; 2,495
responded by mail and received a follow-up telephone call. Of
these, 505 could not be reached, 596 declined participation, and
370 were excluded due to an MI in the prior 6 months, self-
assessed inability to walk one block, or pending move from the
area. Between September 2000 and December 2002, 1,024
patients were enrolled. At their initial study appointment,
patients completed the PHQ-2 and PHQ-9 and were assessed
for current (past month) MDD with the C-DIS. The appropriate
Institutional Review Boards approved all study procedures, and
all participants provided written, informed consent.
The PHQ-9
8,14 includes nine items (scored 0–3; total score
range 0 to 27). The PHQ-2 includes the first two items of the
PHQ-9 (anhedonia and depressed mood) with a total score
range of 0 to 6. For the “PHQ diagnosis,” subjects were
considered depressed if they reported a total of five of nine
PHQ symptoms, including anhedonia or depressed mood,
“more than half the days” (thoughts of death counted if present
at all).
14 The C-DIS was the gold standard used to assess MDD
in the previous month
12,15 by research assistants blind to
results of the PHQ.
Sensitivity, specificity, positive predictive value, negative
predictive value, likelihood ratios, and area under the receiv-
er-operating characteristic curve (AUC)
16 were calculated.
Each of 18 patients was missing one item on the PHQ-9.
Missing values were imputed using the SPSS Missing Values
Analysis module expectation maximization algorithm (version
15.0, Chicago, IL).
RESULTS
A total of 224 patients (22%) had MDD diagnoses. Patient
characteristics, including MDD prevalence by subgroup, are
shown in Table 1. As shown in Table 2, and as previously
reported by McManus et al.,
11 cutoffs for the PHQ-2 (≥3) and
PHQ-9 (≥10) recommended for primary care resulted in good
specificity (93% and 90%, respectively), but poor sensitivity
(39% and 54%, respectively). Optimal cutpoints were ≥2 for
the PHQ-2 (82% sensitive, 79% specific) and ≥6 for the PHQ-9
(83% sensitive, 76% specific). The two-step procedure (PHQ-9
≥6 for patients with PHQ-2 ≥2) resulted in somewhat lower
sensitivity (75%) and somewhat higher specificity (84%) com-
pared to the PHQ-9 or PHQ-2 alone. The “PHQ diagnosis”
approach was highly specific (96%), but poorly sensitive (28%).
There were no significant differences in AUC or sensitivity and
specificity for the PHQ-2 or PHQ-9 based on sex or age (<70
years versus ≥70 years).
DISCUSSION
In outpatients with stable CAD, we found that either a PHQ-2
cutpoint of ≥2 or a PHQ-9 cutpoint of ≥6 optimized combined
sensitivity and specificity for detecting MDD based on a
structured clinical interview. A two-step screening approach
using both instruments had similar overall diagnostic accura-
Table 1. Patient Characteristics and Prevalence of Major
Depressive Disorder (MDD) in Each Subgroup
Characteristic Total sample
(N=1,024):
number (%)
Number (%) in
each subgroup
with MDD
Age
<50 years 58 (6%) 21 (36%)
50–59 years 200 (20%) 74 (37%)
60–69 years 322 (31%) 78 (24%)
70–79 years 321 (31%) 35 (11%)
80 +years 123 (12%) 16 (13%)
Sex
Female 184 (18%) 67 (36%)
Male 840 (82%) 157 (19%)
Race/ethnicity
Non-Hispanic White 615 (60%) 135 (22%)
Hispanic 89 (9%) 25 (28%)
African American 169 (16%) 42 (25%)
Asian or Pacific Islander 118 (12%) 13 (11%)
Other 33 (3%) 9 (27%)
Education
Less than high school 131 (13%) 26 (20%)
High school graduate 182 (18%) 38 (21%)
Some college/junior college/
vocational school
354 (35%) 80 (23%)
College degree 182 (18%) 38 (21%)
Graduate/professional degree 173 (17%) 42 (24%)
Not reported 2 (<1%) 0 (0%)
Annual income (US dollars)
<20,000 498 (49%) 141 (28%)
20,000–29,000 138 (13%) 27 (20%)
30,000–39,000 95 (9%) 16 (17%)
40,000–50,000 98 (10%) 14 (14%)
>50,000 189 (18%) 26 (14%)
Not reported 6 (1%) 0 (0%)
Marital status
Married/partner 436 (43%) 71 (16%)
Divorced 239 (23%) 60 (25%)
Single 191 (19%) 53 (28%)
Widowed 119 (12%) 27 (23%)
Separated 36 (4%) 12 (33%)
Not reported 3 (<1%) 1 (33%)
Medical history:
Hypertension 723 (71%) 158 (22%)
Myocardial infarction 547 (54%) 110 (20%)
Coronary revascularization 602 (59%) 111 (18%)
Congestive heart failure 179 (18%) 40 (22%)
Stroke 148 (15%) 33 (22%)
Diabetes mellitus 265 (26%) 68 (26%)
Regular alcohol use 293 (29%) 67 (23%)
Current smoking 201 (20%) 64 (32%)
NYHA classification
I 377 (37%) 62 (16%)
II 416 (41%) 95 (23%)
III 181 (18%) 49 (27%)
IV 49 (5%) 18 (37%)
Left ventricular ejection fraction
≤50%
113 (11%) 17 (15%)
NYHA = New York Heart Association
2015 Thombs et al: Detecting Depression in Coronary Artery Disease JGIMcy to using either alone. As compared with a structured clinical
interview for MDD, a “PHQ diagnosis” using the PHQ-9
responses to diagnose MDD was highly specific, but resulted
in many false negatives.
Our results build on the work of Stafford et al. who
examined a group of individuals in Australia 3 months after
discharge from hospitalization for an acute MI or a coronary
revascularization procedure.
13 They also found that a PHQ-9
cutoff score of ≥6 optimized sensitivity and specificity. We
added to this work by demonstrating that the PHQ-2 performs
similarly to the PHQ-9 and that two-step screening with the
PHQ-2 followed by the PHQ-9 does not improve results
compared to screening with either the PHQ-2 or the PHQ-9
alone. An obvious benefit to using the PHQ-2 is its relative
brevity. On the other hand, the PHQ-9 may be a better tool for
tracking depressive symptoms over time.
We generated cutoff scores that optimized the balance
between sensitivity and specificity. In clinical settings, scores
can be used to assess depression severity, to monitor the
efficacy of treatment, or to identify patients likely to have a
diagnosis of MDD based on further assessment. Cutoff points
can also be used for research purposes, but not for the formal
diagnosis of MDD. A formal diagnosis of MDD requires a
clinical interview that assesses specific symptom patterns, as
well as evidence of functional limitations.
As demonstrated in primary care settings, improved depres-
sion outcomes are likely to occur only when a collaborative
care model is used, including the use of evidence-based
protocols for treatment, active collaboration between primary
care providers and mental health specialists, active monitoring
of adherence to therapy, and access to structured psychother-
apy.
17 In the absence of these services, there is no evidence
that screening alone is of benefit to patients in CVD settings. It
must be noted, however, that this conclusion is made from the
perspective of depression care alone and does not take into
account the possibility that depression screening may have
other potential benefits to patients with CVD. Many studies
have now shown that patients with positive depression screens
are at increased risk of cardiovascular morbidity and mortal-
ity.
18 If depression screening identifies a group of high-risk
patients who derive particular benefit from certain cardiac
procedures or from interventions focused on enhancing ad-
herence to medication or to secondary prevention behaviors,
for example, then screening may be useful in therapeutic
decision making even in the absence of mechanisms for formal
depression diagnosis, treatment, and follow-up.
It must also be noted that this analysis is based on data
from a study of outpatients with stable CAD, and the degree to
which conclusions generalize to patients hospitalized with
acute coronary syndromes is unknown. Furthermore, since
only 7% of eligible patients actually enrolled in the study,
results may not generalize well to other groups of CAD
patients, although this response rate is comparable to other
large cohort studies, such as the Coronary Artery Disease in
Young Adults Study and the Cardiovascular Health Study.
19,20
Additional research is needed on screening in acute care
settings. Studies are also needed that examine paradigms,
such as multiple positive screens prior to initiating formal
evaluation, with the goal of reducing the high number of false
positives generated in initial screening. Furthermore, clinical
management paradigms are needed to establish whether
screening in cardiovascular care settings leads to net benefits
for patients.
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Table 2. Test Characteristics of Cutoff Scores for the PHQ-2 and PHQ-9, a Two-step Screening Procedure (PHQ-2≥2 Followed by PHQ-9≥6 for
Positive Screens on PHQ-2), and a “PHQ Diagnosis” Approach (Self-report of Five of Nine Symptoms More Than Half the Days in Past 2 Weeks,
Including Anhedonia or Depressed Mood, with Thoughts of Death Counted if Present at All)
Screening
method
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive predictive
value % (95% CI)
Negative predictive
value % (95% CI)
Positive
likelihood ratio
Negative
likelihood ratio
PHQ-2≥1 91 (87–94) 64 (61–68) 42 (37–46) 96 (94–98) 2.56 0.14
PHQ-2≥2 82 (76–86) 79 (76–81) 52 (46–57) 94 (92–95) 3.80 0.23
PHQ-2≥3 39 (33–45) 93 (90–94) 59 (51–67) 84 (82–87) 5.18 0.66
PHQ-9≥4 94 (90–97) 63 (59–66) 41 (37–46) 97 (96–99) 2.52 0.09
PHQ-9≥5 89 (84–92) 71 (67–74) 46 (41–50) 96 (94–97) 3.01 0.16
PHQ-9≥6 83 (78–87) 76 (73–79) 50 (45–55) 94 (92–96) 3.51 0.22
PHQ-9≥7 74 (68–79) 82 (79–84) 53 (47–58) 92 (89–94) 4.01 0.32
PHQ-9≥8 69 (62–74) 84 (82–87) 55 (49–61) 91 (88–93) 4.40 0.37
PHQ-9≥9 61 (54–67) 88 (85–90) 58 (52–64) 89 (86–91) 4.96 0.45
PHQ-9≥10 54 (47–60) 90 (88–92) 61 (54–67) 88 (85–90) 5.54 0.51
Two-step screening 75 (69–81) 84 (81–86) 57 (51–62) 92 (90–94) 4.68 0.29
“PHQ diagnosis” 28 (22-34) 96 (94–97) 65 (55–73) 83 (80–85) 6.51 0.76
Area under the receiver-operating characteristic curve for PHQ-9=0.86 (0.84–0.89) and for PHQ-2=0.84 (0.81–0.87)
CI = confidence interval; PHQ = Patient Health Questionnaire
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